证券简称：康缘药业 证券代码：600557 公告编号：2025-019 江苏康缘药业股份有限公司 关于 2025 年第一季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏康缘药业股份有限公司（以下简称"公司"）根据上海证券交易所发布 的《上海证券交易所上市公司自律监管指引第 3 号—行业信息披露》的相关要求， 现将公司 2025 年第一季度主要经营数据披露如下： 江苏康缘药业股份有限公司董事会 | | | | 毛利 | 营业收入 比上年同 | 营业成本 | 毛利率比上年同期增 | | --- | --- | --- | --- | --- | --- | --- | | 分地区 | 营业收入 | 营业成本 | | | 比上年同 | | | | | | 率（%） | 期增减 | 期增减（%） | 减（%） | | | | | | （%） | | | | 国内销售 | 867,216,343.48 | 222,677,030.89 | 74.32 | -35.79 | -34.35 | 减少 0.57 个 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 877,554,089.34, a decrease of 35.38% compared to CNY 1,359,020,285.93 in the same period last year[5] - Net profit attributable to shareholders was CNY 83,412,980.21, down 38.37% from CNY 148,044,958.72 year-on-year[5] - Basic earnings per share decreased by 34.78% to CNY 0.15 from CNY 0.23 in the previous year[6] - Total operating revenue for Q1 2025 was CNY 877,554,089.34, a decrease of 35.4% compared to CNY 1,358,009,437.31 in Q1 2024[27] - Net profit for Q1 2025 was CNY 85,552,385.18, a decline of 34.9% from CNY 131,428,235.70 in Q1 2024[28] - Basic and diluted earnings per share for Q1 2025 were CNY 0.15, compared to CNY 0.23 in Q1 2024[28] Cash Flow - The net cash flow from operating activities fell by 59.90% to CNY 76,936,099.28, compared to CNY 198,867,926.89 in the same period last year[5] - In Q1 2025, the cash inflow from operating activities was CNY 996,812,504.48, a decrease of 32.5% compared to CNY 1,476,632,797.58 in Q1 2024[30] - The net cash flow from operating activities for Q1 2025 was CNY 76,936,099.28, down 60.1% from CNY 191,883,451.67 in Q1 2024[30] - The cash flow from other operating activities decreased to CNY 43,558,462.11 in Q1 2025 from CNY 93,374,608.68 in Q1 2024, a decline of 53.3%[30] - The company experienced a net decrease in cash and cash equivalents of CNY 73,609,393.53 in Q1 2025, contrasting with an increase of CNY 66,900,832.33 in Q1 2024[31] Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,884,778,092.97, a slight decrease of 0.32% from CNY 6,906,762,381.38 at the end of the previous year[6] - Cash and cash equivalents as of March 31, 2025, were CNY 2,094,172,093.81, down from CNY 2,195,076,101.94 at the end of 2024[23] - Total liabilities as of March 31, 2025, were CNY 2,094,135,216.35, a decrease from CNY 2,201,671,889.94 at the end of 2024[25] - Inventory as of March 31, 2025, was CNY 515,373,930.80, down from CNY 540,269,821.74 at the end of 2024[23] Research and Development - The company reported a significant increase in prepayments by 32.49%, primarily due to increased R&D expenses[9] - The company’s major R&D projects include four innovative biological drugs, with clinical trials showing good safety, tolerability, and preliminary efficacy results[19] - The company’s major focus areas for R&D are metabolic diseases and neurological disorders, with multiple projects in various clinical trial phases[19] - Research and development expenses for Q1 2025 were CNY 131,914,970.39, a decrease from CNY 214,961,528.07 in Q1 2024[27] - The company received clinical trial approval for three new drug indications during the reporting period[18] Shareholder Activities - The top shareholder, Jiangsu Kangyuan Group Co., Ltd., holds 30.94% of the shares, totaling 176,173,467 shares[11] - The company repurchased a total of 12,338,346 shares, with a total payment of RMB 185,909,622.90, and all repurchased shares will be canceled[15] - The company plans to extend the share repurchase period by 9 months, from May 6, 2024, to February 5, 2025, and increase the maximum repurchase price from RMB 18 to RMB 20 per share[14] - The total amount allocated for the share repurchase plan is between RMB 1.5 billion and RMB 3 billion[14] - The company’s stock repurchase plan aims to maintain company value and protect shareholder interests[14] - The company’s controlling shareholder, Nanjing Kangzhu, completed a share increase plan, acquiring 2,478,700 shares for a total of RMB 34,228,626.33[17] - The top shareholder, Jiangsu Kangyuan Group, holds 176,173,467 shares, representing a significant portion of the company's equity[13] - The company has not reported any changes in the participation of major shareholders in margin financing or securities lending activities[13] Investment Activities - The company’s investment activities generated a net cash flow of -CNY 151 million, compared to -CNY 109 million in the previous year, indicating increased investment outflows[9] - The net cash flow from investing activities in Q1 2025 was -CNY 150,552,818.14, compared to -CNY 108,503,090.98 in Q1 2024, indicating a worsening investment cash flow situation[31] - The total cash inflow from investment activities in Q1 2025 was CNY 228,838,490.05, down 55.6% from CNY 514,816,096.34 in Q1 2024[31] - The cash outflow for investment activities in Q1 2025 was CNY 379,391,308.19, a decrease of 39.1% compared to CNY 623,319,187.32 in Q1 2024[31] - The company reported a cash outflow of CNY 16,479,528.36 from financing activities in Q1 2025, with no cash inflow recorded[31]

Group 1 - The core point of the article is that Kangyuan Pharmaceutical (600557) reported a significant decline in both revenue and net profit for the first quarter of 2025 compared to the same period last year [1] Group 2 - The company's revenue for Q1 2025 was 878 million yuan, representing a year-on-year decrease of 35.38% [1] - The net profit for the same period was 83.41 million yuan, showing a year-on-year decline of 38.37% [1]

Investment Rating - The industry investment rating is "Overweight (Maintain)" [1] Core Viewpoints - The report emphasizes the acceleration of domestic substitution and investment opportunities in blood products [3] - The implementation of the "Pharmaceutical Industry Digital Transformation Plan (2025-2030)" aims to enhance the efficiency of drug research and development through artificial intelligence and digital technologies [4][6] - The report suggests focusing on companies such as China Resources Sanjiu, Tasly, and Kangyuan Pharmaceutical due to their potential benefits from the digital transformation in the pharmaceutical industry [6] Summary by Sections Industry Overview - The pharmaceutical and biotechnology industry is currently experiencing a digital transformation, with significant government support and initiatives aimed at modernizing the sector [4][5] Digital Transformation Plan - The plan outlines goals for 2027, including the development of over 100 high-performance products in smart pharmaceutical equipment and the establishment of more than 100 exemplary digital pharmaceutical factories [4] - It also aims to create a comprehensive digital service system to support the transformation of the pharmaceutical industry [4] Investment Opportunities - The report highlights the potential for improved drug development efficiency through AI-assisted drug target discovery and virtual screening of compounds [6] - The focus on traditional Chinese medicine (TCM) is also noted, with the establishment of a traceable data platform for the entire TCM industry chain [5]

Group 1 - Jinchengxin signed a mining production contract with Western Mining for approximately 377 million yuan [1] - Weishinkang's subsidiary received a drug registration certificate for compound amino acid injection (18AA-Ⅸ) [1] - Kangyuan Pharmaceutical obtained a drug registration certificate for Yunu Jian granules [2] Group 2 - Zongheng Communication reported a net profit of 3.42 million yuan in Q1 2025, turning from loss to profit [3] - Phoenix Holdings achieved a net profit of 1.39 million yuan in Q1 2025, also turning from loss to profit [3] - Dayuan Pump Industry reported a net profit of 39.21 million yuan in Q1 2025, a decrease of 3.95% year-on-year [5] Group 3 - Shuo Beid reported a net profit of 14.53 million yuan in Q1 2025, an increase of 276.05% year-on-year [7] - Tongde Chemical reported a net profit of 10.31 million yuan in Q1 2025, a decrease of 51.51% year-on-year [8] - Vanadium Titanium Co. reported a net loss of 98 million yuan in Q1 2025, a decline of 40.84% in revenue [9] Group 4 - Xineng Taishan reported a net profit of 16.23 million yuan in Q1 2025, turning from loss to profit [10] - Andavil reported a net profit of 13.83 million yuan in 2024, a decrease of 87.82% year-on-year [12] - Xingyuan Environment reported a net loss of 302 million yuan in 2024, a reduction in loss by 69.46% [14] Group 5 - China Rare Earth reported a net loss of 287 million yuan in 2024, turning from profit to loss [15] - Zhejiang Huaye reported a net profit of 92.94 million yuan in 2024, an increase of 32.21% year-on-year [16] - Mengjie Co. reported a net profit of 24.88 million yuan in 2024, an increase of 10.99% year-on-year [18] Group 6 - Tongde Chemical reported a net loss of 71.99 million yuan in 2024, turning from profit to loss [19] - Rongsheng Development reported a net loss of 8.44 billion yuan in 2024, turning from profit to loss [21] - Sanwei Communication reported a net loss of 27.1 million yuan in 2024, turning from profit to loss [22] Group 7 - Wankang Technology reported a net loss of 16.3 million yuan in 2024, turning from profit to loss [24] - Huitian New Materials reported a net profit of 1.02 billion yuan in 2024, a decrease of 65.91% year-on-year [25] - Luzhou Laojiao reported a net profit of 13.47 billion yuan in 2024, an increase of 1.71% year-on-year [27] Group 8 - Haiyuan Composite reported a net loss of 16 million yuan in 2024 [29] - Hongchuan Wisdom reported a net profit of 15.8 million yuan in 2024, a decrease of 46.57% year-on-year [30] - Gree Electric reported a net profit of 32.18 billion yuan in 2024, an increase of 10.91% year-on-year [30]

江苏康缘药业股份有限公司 关于获得玉女煎颗粒药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏康缘药业股份有限公司（以下简称"公司"）于近日收到国家药品监督管理 局签发的玉女煎颗粒《药品注册证书》。按照《上海证券交易所上市公司自律监管 指引第 3 号——行业信息披露》的相关要求，现将药品相关情况公告如下： 证券简称：康缘药业 证券代码：600557 公告编号：2025-018 注册分类：中药 3.1 类 是否独家：是 功能主治：清胃热，滋肾阴。用于胃热阴虚证。症见头痛，牙痛，齿松牙衄， 烦热干渴，或消渴，消谷善饥，舌红苔黄而干，脉浮洪或滑。 药品有效期：24 个月 处方药/非处方药：处方药 药品注册标准编号：YBZ00102025 一、药品基本情况 药品通用名称：玉女煎颗粒 主要成份：石膏、熟地黄、麦冬、知母等 剂型：颗粒剂 规格：每袋装 8g（相当于饮片 28.92g） 江苏康缘药业股份有限公司董事会 药品批准文号：国药准字 C20250006 1 药品生产企业：江苏康缘药业股份有限公司 二、药品研发及 ...

证券代码：600557 证券简称：康缘药业 公告编号：2025-016 江苏康缘药业股份有限公司 2024年年度股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东会召开的时间：2025 年 04 月 24 日 (二)股东会召开的地点：连云港经济技术开发区江宁工业城公司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 300 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 264,447,957 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 46.4384 | | 份总数的比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 重要内容提示： 本次会议由公司董事会召集，董事长肖伟先生主持，会议采取现场投票和网 络投票相结合的表决方式。会议的召集、召开和表决符合《公司法》及《公司章 程》的规定 ...

证券简称：康缘药业 证券代码：600557 公告编号：2025-017 本议案分项表决结果为： （一）调整第八届董事会审计委员会委员 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏康缘药业股份有限公司（简称"公司"）第八届董事会第十七次会议通知 于 2025 年 4 月 14 日以书面文件、电话和电子邮件方式发出，会议于 2025 年 4 月 24 日在公司会议室以现场结合通讯方式召开。应出席会议董事 9 人，实际出席会 议董事 9 人。本次会议的召开符合《公司法》等法律法规以及《公司章程》的规定。 会议由董事长肖伟先生主持，会议以举手和通讯表决的方式审议通过以下议案，并 形成决议。 一、审议通过了《关于调整董事会专门委员会委员的议案》 公司 2024 年年度股东会选举孙晓波先生、吕爱平先生为公司第八届董事会独 立董事，鉴于公司第八届董事会成员发生变动，为保证董事会各专门委员会有序高 效开展工作，根据《公司法》《公司章程》《董事会审计委员会工作细则》《董事 会战略委员会工作细则》等规定，拟补选孙晓波先生为公司第八届董事会 ...

康缘药业 2024 年年度股东会 法律意见书 江苏世纪同仁律师事务所 关于江苏康缘药业股份有限公司 2024 年年度股东会的法律意见书 江苏康缘药业股份有限公司： 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》《上市公司股东会规则》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等法律、法规和规范性文件以及《公司章程》的规定，本所受 公司董事会的委托，指派本所律师出席公司 2024 年年度股东会，并就本次股东 会的召集、召开程序、出席会议人员资格、召集人资格、表决程序以及表决结果 等事项的合法有效性出具法律意见。 为出具本法律意见书，本律师对本次股东会所涉及的有关事项进行了审查， 查阅了相关会议文件，并对有关问题进行了必要的核查和验证。 本律师同意将本法律意见书随公司本次股东会决议一并公告，并依法对本法 律意见书承担相应的责任。 本律师根据相关法律、法规和规范性文件的要求，按照律师行业公认的业务 标准、道德规范和勤勉尽责精神，出具法律意见如下： 一、关于本次股东会的召集和召开 1、本次股东会由公司董事会召集 本次股东会由董事会召集。2025 年 4 月 3 日， ...

江苏康缘药业股份有限公司 股东会议事规则 第一章 总 则 第一条 为规范公司的议事方式和程序，保证股东会依法行使职权，根据《中 华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》（以下 简称《证券法》）、《江苏康缘药业股份有限公司章程》（以下简称《公司章程》） 和其他有关法律、法规、规范性文件的规定，制定本规则。 第二条 公司股东会的召集、提案、通知、召开等事项适用本规则。 第三条 公司应当严格按照法律、行政法规、本规则及《公司章程》的相关 规定召开股东会，保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应当 勤勉尽责，确保股东会正常召开和依法行使职权。 第四条 股东会应当在《公司法》和《公司章程》规定的范围内行使职权。 第五条 股东会分为年度股东会和临时股东会。年度股东会每年召开一次， 应当于上一会计年度结束后的六个月内举行。临时股东会不定期召开，出现《公 司法》规定的应当召开临时股东会的情形时，临时股东会应当在两个月内召开。 公司在上述期限内不能召开股东会的，应当报告公司所在地中国证券监督管 理委员会（以下简称"中国证监会"）派出机构和上海证券交 ...